
07/25/2025
IIT has officially launched its participation in the global Phase 3 COMPASS Pathways clinical trial studying psilocybin therapy for treatment-resistant depression. We’re honored to be one of a select group of sites in the world contributing to this historic research.
This trial represents the most advanced clinical investigation of psilocybin for depression to date and has the potential to reshape how we treat severe mental illness. It’s also a major milestone for IIT, which began as a ketamine-assisted psychotherapy clinic and has now expanded into a full-scale psychedelic medicine research company.
IIT launches psilocybin depression trial as part of COMPASS Pathways’ global Phase 3 study on treatment-resistant depression.